CD33 and hematologic disorder: For hematologic malignancies, such as ADCs targeting CD33, high antigen expression in both leukemic and normal hematopoietic progenitor cells likely explains the trend toward increased grade ≥3 AEs observed with DNA-damaging payloads [24].